Skip to main content
Premium Trial:

Request an Annual Quote

US Regulators Clear GE Healthcare's $580M Purchase of Clarient

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Federal Trade Commission has cleared the way for GE Healthcare's purchase of molecular diagnostics and imaging firm Clarient.

The FTC this week granted GE Healthcare early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, removing antitrust barriers in the US to the cash deal, estimated at $570 million to $580 million.

The proposed acquisition was announced in October. At the time, GE Healthcare said that its diagnostic imaging capabilities combined with Clarient's technologies would hasten development of new integrated tools for diagnosing and characterizing cancer. It added that the global market for cancer-profiling products and services is forecast to increase to $47 million by 2015 from $15 million in 2009.

GE Healthcare has said the deal is expected to close later this year or early in 2011.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more